Business Case: New Life Sciences Organization Creates $95.697M in Value with Novel Product

A life sciences organization specializing in pneumothorax recovery


sponsor accepted valuationimproved EPM cycles

ChallengeThis organization designed and prototyped a novel pneumothorax device that moved the partners into unfamiliar roles. The adoption of unfamiliar business roles limited their ability to grow, obtain stakeholder engagement, and necessary funding. PSS Ltd. senior leaders were brought in to identify and deliver missing items.

DiscoveryWorking closely with the client, using a fit-for-purpose and the most effective approach, we aligned on strategy and operational items to address the growth, stakeholder engagement and funding issues. Our team lead several initiatives leveraging existing competencies and accomplishments. Some of the projects involved:
Built business model – by aligning on and building the AS-IS version, and completing hypothesis testing to identify and draft the TO-BE version. Included business development.
Increased efficiency – by developing the first-ever “agile” animal testing methodology.
Clarified and developed corporate governance and compliance – by clarifying their regulatory and patent processes and completing the steps, coaching and advising the executive partners on leadership, management, collaboration and business strategy and growth.
Developed quality management – by drafting quality management processes with role assignments and accountabilities, drafting animal and human trial testing strategy, plan, and standard operating procedures, and completing solutions options analysis for an eQMS tool selection.
Built corporate finance – by completing financial model (planning and analysis, pricing, CLV, other), and capital structure management.
Developed talent – by designing organization processes, developing organization chart and staff roles & responsibilities, and hiring talent.
Established enterprise performance management – by identifying key metrics, and delivering a simple and fit-for-purpose tool for monitoring them.

Value createdAs a result of this transformation, this organization realized immediate and long-term financial and strategic benefits.
Sponsor accepted valuation of $95.697M.
Improved EPM by 55% through quickening learnings application and testing cycles.
Achieved continued engagement of key sponsors, next round financing, and US and CAN regulator acceptance and patent.